Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

varespladib methyl

 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

A-002LY 315920

Broader (3)

AcetatesIndolesPhospholipase A2 Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme family of phospholipase A2 produced by the inflammatory cell in… Expand
Review
2013
Review
2013
Emerging anti-inflammatory drugs for atherosclerosis
Introduction: Cardiovascular disease is the most common cause of morbidity and mortality worldwide. Inflammation is responsible… Expand
2011
2011
Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome
PurposeSecretory phospholipase A2 group IIA (sPLA2−IIA) concentration and activity are associated with increased risk of… Expand
  • table 1
  • table 2
  • figure 3
  • figure 1
  • figure 2
2011
2011
Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA…
BackgroundThe action of secretory phospholipase A2 (sPLA2) on lipoproteins may render them more susceptible to oxidation, thereby… Expand
  • table 1
Highly Cited
2011
Highly Cited
2011
Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
AIMS To investigate the effects of secretory phospholipase A2 (sPLA(2)) inhibition on plasma lipoproteins. Secretory… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
2011
2011
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Secretory phospholipase A(2) (sPLA(2)) represents a family of isoenzymes that participate in lipoprotein and inflammatory… Expand
Highly Cited
2010
Highly Cited
2010
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
OBJECTIVES The purpose of this study was to investigate the effects of varespladib on cardiovascular biomarkers in acute coronary… Expand
  • table 2
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2010
Review
2010
Varespladib methyl in cardiovascular disease
Importance of the field: The high risk of recurrent cardiovascular events amongst patients with cardiovascular disease receiving… Expand
Review
2010
Review
2010
Secretory Phospholipase A2 and Lipoprotein-Associated Phospholipase A2 as Biomarkers of Cardiovascular Disease and Therapeutic Targets
Atherosclerosis is not only a lipid-driven disease but it is an intricate process that also involves the simultaneous and… Expand
2009
2009
Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE